|
151 |
Pretreatment blast-to-lymphocyte ratio as a prognostic marker for CD19/CD3-bispecific T cell-engaging antibodies (blinatumomab) treatment against relapsed or refractory B-precursor acute lymphoblastic leukemia
Enthalten in Cancer immunology immunotherapy Bd. 72, 7.8.2023, Nr. 11, date:11.2023: 3861-3865
|
|
|
|
152 |
QSP modeling of loncastuximab tesirine with T-cell-dependent bispecific antibodies guides dose-regimen strategy
Enthalten in npj Systems biology and applications Bd. 11, 11.6.2025, Nr. 1, date:12.2025: 1-9
|
|
|
|
153 |
Rapid Purification of Human Bispecific Antibodies via Selective Modulation of Protein A Binding
Enthalten in Scientific reports Bd. 7, 14.11.2017, Nr. 1, date:12.2017: 1-11
|
|
|
|
154 |
Recent advancements at ASCO 2024 in PD-L1 and PD-1 bispecific antibodies
Enthalten in Medical oncology Bd. 42, 17.11.2024, Nr. 1, date:1.2025: 1-7
|
|
|
|
155 |
Recent advances and challenges of bispecific antibodies in solid tumors
Enthalten in Experimental hematology & oncology Bd. 10, 18.12.2021, Nr. 1, date:12.2021: 1-14
|
|
|
|
156 |
Recent advances of bispecific antibodies in solid tumors
Enthalten in Journal of hematology & oncology Bd. 10, 20.9.2017, Nr. 1, date:12.2017: 1-16
|
|
|
|
157 |
Recent Advances on Immune Targeted Therapy of Colorectal Cancer Using bi-Specific Antibodies and Therapeutic Vaccines
Enthalten in Biological procedures online Bd. 23, 1.7.2021, Nr. 1, date:12.2021: 1-13
|
|
|
|
158 |
Safety and efficacy of T-cell-redirecting bispecific antibodies for patients with multiple myeloma: a systematic review and meta-analysis
Enthalten in Cancer cell international Bd. 23, 5.9.2023, Nr. 1, date:12.2023: 1-14
|
|
|
|
159 |
γ-secretase inhibitors augment efficacy of BCMA-targeting bispecific antibodies against multiple myeloma cells without impairing T-cell activation and differentiation
Enthalten in Blood cancer journal Bd. 12, 16.8.2022, Nr. 8, date:8.2022: 1-10
|
|
|
|
160 |
Simultaneous multiple interaction T-cell engaging (SMITE) bispecific antibodies overcome bispecific T-cell engager (BiTE) resistance via CD28 co-stimulation
Enthalten in Leukemia Bd. 32, 31.1.2018, Nr. 5, date:5.2018: 1239-1243
|
|
Administration
